myTomorrows’ Post

𝐓𝐨𝐩 𝐑&𝐃 𝐒𝐩𝐞𝐧𝐝𝐞𝐫𝐬 𝐢𝐧 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 Research and Development (R&D) is the lifeblood of the #pharmaceutical industry. Significant investments in R&D are crucial for discovering new medicines and therapies that improve patient outcomes and address unmet medical needs. Companies that prioritize R&D spending are better positioned to take the lead in future developments. I previously wrote about the top R&D spenders in #medtech industry. I thought it would be good to do the same exercise for the pharmaceutical and biotech companies. The followings are top R&D spenders in #Biopharma industry: 16- Novo Nordisk $4.7B 15- Amgen $4.8B 14- Takeda $5B 13- Gilead Sciences $5.7B 12- Bayer $5.8B 11- Sanofi $7.3B 10- AbbVie $7.7B 9- GSK 7.7B 8- Bristol Myers Squibb $9.3B 7- Eli Lilly and Company $9.3B 6- Pfizer $10.7B 5- AstraZeneca $10.9B 4- Novartis $11.4B 3- Johnson & Johnson $15.1B 2- Roche $15.8B 1- Merck $30.5B In general, pharmaceutical companies spend a higher percentage of their revenue on R&D activities. Top R&D spender in pharmaceutical industry spends 10x more than the top R&D spender in medtech industry. Would be interesting to see how/if these numbers change in coming years. * Views and ideas are my own. The content that I provide here are public data and intended to be educational only and are not endorsement or financial advice. I always encourage the readers to do their own research. This visualization was inspired by Quartr.

R&D is pivotal in pharmaceutical innovation, driving the discovery of new medicines and therapies that address unmet medical needs. Companies investing significantly in R&D are better positioned for future developments, leading to improved patient outcomes. #reimagingmedicine #pharmaceuticalinnovation

Part 2: The Conflict of Interest in Drug Research: The Challenge of Incentives in Clinical Services Partnerships The landscape of pharmaceutical research and development is deeply entrenched in a complex web of partnerships and collaborations. However, a critical issue that often goes unnoticed is the misalignment of incentives within the clinical research ecosystem, particularly among Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), and other key clinical services companies. The core of this issue lies in the lack of incentive for these partners to optimize the efficiency and accuracy of drug trials, as doing so may directly impact their revenues. The perpetuation of prolonged and less nimble research not only results in inflated costs but also poses a significant hurdle in getting life-saving medications to patients in need swiftly and efficiently. This presents a formidable barrier to the pursuit of streamlined and agile drug development, impacting both the industry's ability to innovate and the timely delivery of critical treatments. In light of the stark contrast in stock performance between Thermo Fisher Scientific (TMO) and Pfizer (PFE) over the past 20 years, where TMO showcased a striking 2000% increase while PFE experienced a consequential 25% decrease, the need for a shift in the incentives and partnerships becomes even more apparent. It is imperative to acknowledge that the ability to leverage objective medication adherence data insights is a crucial differentiator in this disparity. Companies like Information Mediary Corp, striving to transform clinical research with their smart packaging-based adherence insights, face the challenge of a misaligned partnership landscape that limits the widespread adoption of transformative technologies. It is time to initiate a dialogue that challenges the status quo and encourages a redefined partnership model—an approach that aligns the interests of all parties involved. This paradigm shift calls for a collaborative effort to cultivate a culture of shared value and innovative solutions in drug research partnerships. By doing so, we can pave the way for a future where efficiency and impact align seamlessly, driving substantial advancements in drug development. The pharmaceutical industry stands at a crucial juncture, demanding a pivotal shift in the dynamics between research teams and their clinical services partners. Let's strive for a future where the pursuit of efficiency and impact is mutually beneficial, revolutionizing the landscape of drug development. This is our opportunity to carve a new path—a path unencumbered by conflicting interests and fueled by the promise of collaborative success in drug research. The graph speaks for itself. #cfo #clincialtrial #drugdevelopment #medicationadherence

𝐓𝐨𝐩 𝐑&𝐃 𝐒𝐩𝐞𝐧𝐝𝐞𝐫𝐬 𝐢𝐧 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 Research and Development (R&D) is the lifeblood of the #pharmaceutical industry. Significant investments in R&D are crucial for discovering new medicines and therapies that improve patient outcomes and address unmet medical needs. Companies that prioritize R&D spending are better positioned to take the lead in future developments. I previously wrote about the top R&D spenders in #medtech industry. I thought it would be good to do the same exercise for the pharmaceutical and biotech companies. The followings are top R&D spenders in #Biopharma industry: 16- Novo Nordisk $4.7B 15- Amgen $4.8B 14- Takeda $5B 13- Gilead Sciences $5.7B 12- Bayer $5.8B 11- Sanofi $7.3B 10- AbbVie $7.7B 9- GSK 7.7B 8- Bristol Myers Squibb $9.3B 7- Eli Lilly and Company $9.3B 6- Pfizer $10.7B 5- AstraZeneca $10.9B 4- Novartis $11.4B 3- Johnson & Johnson $15.1B 2- Roche $15.8B 1- Merck $30.5B In general, pharmaceutical companies spend a higher percentage of their revenue on R&D activities. Top R&D spender in pharmaceutical industry spends 10x more than the top R&D spender in medtech industry. Would be interesting to see how/if these numbers change in coming years. * Views and ideas are my own. The content that I provide here are public data and intended to be educational only and are not endorsement or financial advice. I always encourage the readers to do their own research. This visualization was inspired by Quartr.

Revolutionizing Drug Development 🚀 Imagine cutting 6 months or more off the clinical research timeline for solid dose oral drugs. Well, it's not just a dream – it's a reality! CertiScan, an advanced research tool set from Information Mediary Corp, has achieved a groundbreaking leap in drug development through the integration of advanced medication adherence smart blisters and cutting-edge adherence analytics. Major Big Pharma research teams have already recognized the potential of this game-changing technology. In blockbuster drug trials, these innovative solutions have been leveraged to derisk and significantly speed up #fda submissions and approvals, redefining the landscape of pharmaceutical innovation. By harnessing the power of advanced medication adherence smart blisters and adherence analytics, #certiscan is empowering research teams to gain unprecedented insights into patient behavior and medication adherence. This not only accelerates the collection of crucial data but also de-risks the drug development process, leading to more robust FDA submissions and expediting the path to market approval. The impact of this advancement is far-reaching, promising faster access to life-saving medications for patients in need. With CertiScan at the forefront of this groundbreaking transformation, we're witnessing a seismic shift in the way drug development is approached, driving improved health outcomes and revolutionizing the healthcare landscape. As the industry continues to embrace this cutting-edge technology, CertiScan is proud to be at the forefront of propelling drug development into a new era of efficiency and innovation. Join us in celebrating this remarkable accomplishment and stay tuned for more updates as we continue to reshape the future of pharmaceutical research and development. #drugdevelopment #Innovation #HealthcareAdvancement #fdaapproval #certiscan #clinicalresearch

This years Forum, organised by The Galien Foundation, promises some really interesting and topical discussions. We are increasingly working with companies who are placing greater emphasis on the patient voice in R&D and it will be good to hear regulatory, industry and patient perspectives on the panel chaired by Mel Walker #Patientengagenent #Pharmaceuticals

In a world where the healthcare industry is ever-evolving, we need forward-thinking companies to pioneer future research and advancement. One such firm that is standing out is 6S Pharma Inc. Solutions Pvt Ltd. A pharmaceutical research powerhouse headed by founders Ashok Illapakurthy and Krishna Devarakonda. With an IND stage company and a series of 505 b2 products in the pipeline, 6S Pharma is setting the pace for innovation in healthcare solutions. Their dedication and commitment to improving lives, advancing the field of medicine and creating novel pharmaceutical products and therapies make them leaders in their industry. Are they shaping the future of pharma research? Delve into their story, understand their research strategies, and the impact they create in this insightful article. A must-read for everyone in the health care and pharmaceutical industries! Check it out here: https://lnkd.in/ehRkYbqs Bringing a revolution, one research at a time! #HealthTech #PharmaTrends #Innovation #Pharmaceuticals #HealthcareSolutions #6SPharma #PioneeringResearch.

🌟 Exciting News in the Pharmaceutical Industry! 🌟 AstraZeneca recently announced its ambitious goal to achieve $80 billion in sales by 2030. This is a major milestone in the company's growth strategy and reflects its commitment to innovation and improving patient outcomes. With a strong focus on research and development, AstraZeneca is determined to make groundbreaking advancements in healthcare and bring life-changing treatments to patients worldwide. The company's dedication to addressing unmet medical needs is truly commendable, and this ambitious sales target underscores their confidence in the value of their pipeline and portfolio. As AstraZeneca continues to expand its reach and capabilities, it's evident that they are at the forefront of driving positive change in the healthcare landscape. Their drive to reach the $80 billion sales goal by 2030 is not only a testament to their vision and leadership but also a testament to their commitment to making a meaningful impact on global health. This bold aim from AstraZeneca sets a high bar for the industry, inspiring innovation and transformative advancements. Let's all show our support and stay tuned for the remarkable developments ahead! #AstraZeneca #PharmaceuticalIndustry #HealthcareInnovation #SalesGoals #GlobalHealth #ResearchAndDevelopment 🚀🔬 Note: AI-powered post. May contain errors.

Putting Patients at the Heart of Drug Development We're thrilled to announce the first-panel discussion at the prestigious Prix Galien UK 2024 awards ceremony titled "No Decision for Me Without Me: Putting Patients at the Heart of Drug Development." At Galien, we firmly believe that patients must have a voice in the process of developing new medicines that impact their lives. This panel brings together renowned experts spanning patient advocacy, regulatory bodies, and pharmaceutical R&D to explore how we can truly embed the patient perspective throughout the drug development journey. Our esteemed panelists include: Panel Chair: Dr. Mel Walker Strategic Advisor and Managing Director at BioPharma Futures Panelists: 1. Robyn Bent, Director of CDER's Patient-Focused Drug Development Program at FDA 2. Dr. Sarah Gheuens, Chief Medical Officer and Head of R&D at Agios Pharmaceuticals 3. Dr. Maria Mavris, Patient Liaison at European Medicines Agency 4. Elizabeth Vroom, Co-founder and Chair of World Duchenne Organization Join us as we dive into best practices for meaningful patient engagement, discuss regulatory initiatives promoting patient-centricity, and explore innovative ways to amplify the patient voice from drug discovery through commercialization. The path to developing transformative medicines lies in listening to and co-creating solutions with those most impacted. This panel reflects our commitment to that ideal. Follow us at The Galien Foundation for live updates and insights from this must-attend session. #PrixGalienUK2024 #PatientCentricInnovation

𝐓𝐨𝐩 𝐑&𝐃 𝐒𝐩𝐞𝐧𝐝𝐞𝐫𝐬 𝐢𝐧 𝐁𝐢𝐨𝐩𝐡𝐚𝐫𝐦𝐚 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 Research and Development (R&D) is the lifeblood of the #pharmaceutical industry. Significant R&D investments are crucial for discovering new medicines and therapies that improve patient outcomes and address unmet medical needs. Companies that prioritize R&D spending are better positioned to take the lead in future developments. I previously wrote about the top R&D spenders in the #medtech industry. I thought it would be good to do the same exercise for the pharmaceutical and biotech companies. The following are top R&D spenders in the #Biopharma industry: 16- Novo Nordisk $4.7B 15- Amgen $4.8B 14- Takeda $5B 13- Gilead Sciences $5.7B 12- Bayer $5.8B 11- Sanofi $7.3B 10- AbbVie $7.7B 9- GSK 7.7B 8- Bristol Myers Squibb $9.3B 7- Eli Lilly Italia and Company $9.3B 6- Pfizer $10.7B 5- AstraZeneca $10.9B 4- Novartis $11.4B 3- Johnson & Johnson $15.1B 2- Roche $15.8B 1- Merck $30.5B In general, pharmaceutical companies spend a higher percentage of their revenue on R&D activities. The top R&D spender in the pharmaceutical industry spends 10x more than the top R&D spender in the medtech industry. Would be interesting to see how/if these numbers change in the coming years. Credits: Share your insights in the comment box "Inclusion of innovative approach in today's patient care"